SELLAS Life Sciences (SLS) Liabilities and Shareholders Equity (2010 - 2026)

SELLAS Life Sciences (SLS) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $114.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 226.63% year-over-year to $114.2 million; the TTM figure through Mar 2026 stood at $276.4 million (up 187.86% YoY), while the FY2025 annual figure was $78.3 million, up 303.18% from the prior year.
• Liabilities and Shareholders Equity improved to $114.2 million in Q1 2026 per SLS's latest filing, from $78.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $114.2 million in Q1 2026 and bottomed at $6.2 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $32.9 million across 5 years, with a median of $26.0 million in 2022.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity plunged 70.31% — and 2025, when it surged 303.18%.
• SELLAS Life Sciences' Liabilities and Shareholders Equity stood at $20.9 million in 2022, then slumped by 70.31% to $6.2 million in 2023, then soared by 212.46% to $19.4 million in 2024, then soared by 303.18% to $78.3 million in 2025, then jumped by 45.74% to $114.2 million in 2026.
• Business Quant data shows SLS's Liabilities and Shareholders Equity at $114.2 million in Q1 2026, $78.3 million in Q4 2025, and $51.6 million in Q3 2025.